Search

Your search keyword '"Bal L"' showing total 43 results

Search Constraints

Start Over You searched for: Author "Bal L" Remove constraint Author: "Bal L" Topic prostatic neoplasms Remove constraint Topic: prostatic neoplasms
43 results on '"Bal L"'

Search Results

1. Quantitative analysis of radiosensitizing effect for magnetic hyperthermia-radiation combined therapy on prostate cancer cells.

2. Targeting Mitochondrial Metabolism in Prostate Cancer with Triterpenoids.

3. Inhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival.

4. The andean anticancer herbal product BIRM causes destabilization of androgen receptor and induces caspase-8 mediated-apoptosis in prostate cancer.

5. β-Arrestin-2 Counters CXCR7-Mediated EGFR Transactivation and Proliferation.

6. Chemokines and chemokine receptors as promoters of prostate cancer growth and progression.

7. The IL-8-regulated chemokine receptor CXCR7 stimulates EGFR signaling to promote prostate cancer growth.

8. CXC receptor-1 silencing inhibits androgen-independent prostate cancer.

9. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs.

10. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence.

11. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer.

12. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence.

13. Insulin-like growth factors and their binding proteins in prostate cancer: cause or consequence?

14. HYAL1 hyaluronidase in prostate cancer: a tumor promoter and suppressor.

15. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells.

16. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs.

17. The prostate 25-hydroxyvitamin D-1 alpha-hydroxylase is not influenced by parathyroid hormone and calcium: implications for prostate cancer chemoprevention by vitamin D.

18. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer.

19. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer.

20. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model.

21. Targeting Mitochondrial Metabolism in Prostate Cancer with Triterpenoids

22. Inhibition of androgen receptor promotes CXC-chemokine receptor 7-mediated prostate cancer cell survival

23. Chemokines and Chemokine Receptors as Promoters of Prostate Cancer Growth and Progression

24. CXC Receptor-1 Silencing Inhibits Androgen-Independent Prostate Cancer

25. Osteopontin and Interleukin-8 Expression is Independently Associated with Prostate Cancer Recurrence

26. Insulin-like growth factors and their binding proteins in prostate cancer: Cause or consequence?☆

27. Cyclooxygenase-2 (cox-2) expression is an independent predictor of prostate cancer recurrence

28. Inhibition of cell proliferation, invasion, tumor growth and metastasis by an oral non-antimicrobial tetracycline analog (COL-3) in a metastatic prostate cancer model

29. Stromal and Epithelial Expression of Tumor Markers Hyaluronic Acid and HYAL1 Hyaluronidase in Prostate Cancer

30. MMP Inhibition in Prostate Cancer

31. The IL-8 regulated Chemokine Receptor CXCR7 Stimulates EGFR Signaling to Promote Prostate Cancer Growth

32. Chemically modified non-antimicrobial tetracyclines are multifunctional drugs against advanced cancers

33. Depletion of intrinsic expression of Interleukin-8 in prostate cancer cells causes cell cycle arrest, spontaneous apoptosis and increases the efficacy of chemotherapeutic drugs

34. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer

35. Cyclooxygenase-2 inhibitor celecoxib augments chemotherapeutic drug-induced apoptosis by enhancing activation of caspase-3 and -9 in prostate cancer cells

36. Inhibition of cyclooxygenase (COX)-2 expression by Tet-inducible COX-2 antisense cDNA in hormone-refractory prostate cancer significantly slows tumor growth and improves efficacy of chemotherapeutic drugs

37. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer

38. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer

39. Cytotoxic activity and inhibition of tumor cell invasion by derivatives of a chemically modified tetracycline CMT-3 (COL-3)

40. CMT-3, a chemically modified tetracycline, inhibits bony metastases and delays the development of paraplegia in a rat model of prostate cancer

41. Interaction between stromal cells and tumor cells induces chemoresistance and matrix metalloproteinase secretion

42. Modulation of aromatase activity by growth factors in an androgen sensitive human prostate cancer cell line, LNCaP

43. Inhibition of aromatase activity and growth suppression by 4-methoxy-4-androstene-3,17-dione in an androgen sensitive human prostatic carcinoma cell line

Catalog

Books, media, physical & digital resources